T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse

References

• Fenske TS, Hari PN, Carreras J, et al. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant 2009;15:1455–1464.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, van Besien K, Khouri I, et al. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for hig-risk malignant lymphoma. Ann Oncol 1999;10:527–532.
   PubMed Web of Science ®Google Scholar
• van Besien K, Thall P, Korbling M, et al. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant 1997;3:150–156.
   PubMedGoogle Scholar
• Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002;99:1071–1078.
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. Cytotherapy 2001;3:197–201.
   PubMed Web of Science ®Google Scholar
• Perez-Simon JA, Kottaridis PD, Martino R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002;100:3121–3127.
   PubMed Web of Science ®Google Scholar
• Faulkner RD, Craddock C, Byrne JL, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004;103:428–434.
   PubMed Web of Science ®Google Scholar
• van Besien K, Artz A, Smith S, et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005;23:5728–5738.
   PubMed Web of Science ®Google Scholar
• Thomson KJ, Morris EC, Milligan D, et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010;28:3695–3700.
   PubMed Web of Science ®Google Scholar
• Lim ZY, Pearce L, Ho AY, et al. Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. Br J Haematol 2007;138:517–526.
   PubMed Web of Science ®Google Scholar
• van Besien K, Dew A, Lin S, et al. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma 2009;50:1809–1817.
   PubMed Web of Science ®Google Scholar
• van Besien K, Kline J, Godley LA, et al. Phase I-II study of clofarabine-melphalan-alemtuzumab (CMA) conditioning for allogeneic hematopoietic cell transplantation (HCT) in patients with advanced hematologic malignancies: determination of MTD and outcomes. Blood 2009;114(Suppl. 1): Abstract 197.
   Google Scholar
• O'Donnell PH, Artz AS, Undevia SD, et al. Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. Leuk Lymphoma 2010 Oct 4. [Epub ahead of print].
   Web of Science ®Google Scholar
• Kline J, Pollyea DA, Stock W, et al. Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning. Bone Marrow Transplant 2006;37:307–310.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007;25:571–578.
   PubMed Web of Science ®Google Scholar
• Artz A, Pollyea D, Kocherginsky M, et al. Performance status and comorbidity predict transplant related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006;12:954–964.
   PubMed Web of Science ®Google Scholar
• Novitzky N, Thomas V. Allogeneic stem cell transplantation with T cell-depleted grafts for lymphoproliferative malignancies. Biol Blood Marrow Transplant 2007;13:107–115.
   PubMed Web of Science ®Google Scholar
• Morris E, Thomson K, Craddock C, et al. Outcome following alemtuzumab (CAMPATH-1H)-containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkin's lymphoma (NHL). Blood 2004;104:3865–3871.
   PubMed Web of Science ®Google Scholar
• Thomson KJ, Morris EC, Bloor A, et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009;27:426–432.
   PubMed Web of Science ®Google Scholar
• Armand P, Kim HT, Ho VT, et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008;14:418–425.
   PubMed Web of Science ®Google Scholar
• Ingram W, Devereux S, Das-Gupta EP, et al. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. Br J Haematol 2008;141:235–243.
   PubMed Web of Science ®Google Scholar
• Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002;100:4310–4316.
   PubMed Web of Science ®Google Scholar
• Vigouroux S, Michallet M, Porcher R, et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2007;92:627–634.
   PubMed Web of Science ®Google Scholar
• Becherer A, Mitterbauer M, Jaeger U, et al. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia 2002;16:260–267.
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003;102:53–59.
   PubMed Web of Science ®Google Scholar
• Svoboda J, Andreadis C, Elstrom R, et al. Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 2006;38:211–216.
   PubMed Web of Science ®Google Scholar
• Lambert JR, Bomanji JB, Peggs KS, et al. Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood 2010;115: 2763–2768.
   PubMed Web of Science ®Google Scholar
• Thomas A, Gingrich RD, Smith BJ, et al. 18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of ‘indeterminate’ reports. Leuk Lymphoma 2010;51:439–446.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Juweid ME, Schoder H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood 2010;115:775–777.
   PubMed Web of Science ®Google Scholar
• Porter DL, Alyea EP, Antin JH, et al. NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2010;16:1467–1503.
   PubMed Web of Science ®Google Scholar